Clinical Trial: Sorafenib in Relapsed High Grade Osteosarcoma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.

Brief Summary: Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy

Detailed Summary:
Sponsor: Italian Sarcoma Group

Current Primary Outcome: Tumor assessment through radiologic evaluation. [ Time Frame: every 8 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Italian Sarcoma Group

Dates:
Date Received: April 27, 2009
Date Started: January 2008
Date Completion:
Last Updated: March 26, 2013
Last Verified: March 2013